Moderna’s experimental mRNA cancer vaccine, intismeran, is showing early promise when paired with Merck’s Keytruda—potentially offering personalized tumor targeting for melanoma patients and marking a historic leap in oncology.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/3ba1b9ed6ba67637

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av, eller tillsammans med, Poddtoppen.